Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
September 2021
-
Photographer Captures Patients Around the World Persevering With ITP
To showcase how people living with ITP triumph and persevere, Novartis partnered with photographer Kate T. Parker on a series of photo essays.
-
Toward regrowing cartilage
Novartis researchers aim to improve the lives of patients with osteoarthritis.
-
Doing the right thing is good business
Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.
-
Media ReleaseNovartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancerBiologics License Application (BLA) submission supported by Phase III RATIONALE 302 trial, which met primary endpoint of improvement in overall survival (OS) in people with advanced or metastatic…
-
Media ReleaseSandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicineSandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading…
-
A blood cancer patient’s long road to diagnosis
Ilona, a patient living with polycythemia vera, shares her experiences with this rare blood cancer
-
Pulse UpdateNovartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
-
Media ReleaseNovartis presents new findings at ERS reinforcing the efficacy of Enerzair® Breezhaler®, highlighting its digital companion, as well as showcasing commitment to low carbon footprint asthma solutionsNovartis will present 12 abstracts at the European Respiratory Society (ERS) International Congress 2021 for Enerzair® Breezhaler® (IND/GLY/MF*) and Atectura® Breezhaler® (IND/MF**) — for…
-
Pulse UpdateNovartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
-
Media ReleaseWorld-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three…
August 2021
-
Media ReleaseNovartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVDSeparate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio® (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with…
-
Pulse UpdateNovartis sabatolimab receives orphan drug designation from the European Commission for myelodysplastic syndromes
Pagination
- ‹ Previous page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- …
- 151
- › Next page